At Stallergenes Greer,
we partner with Health
Care Professionals to
support patients
through their
treatment cycle
Go Inside Actair
*Standardized house dust mite allergen extracts from: Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the Summary of Product Characteristics
for how to report adverse reactions.
2024_014EN01_May 2024
Actair® allergen extracts
mimic the diverse real-life
exposure of patients allergic
to House Dust Mites.1,2
Actair® is a sublingual
immunotherapy tablet with
a flexible initiation protocol
to improve tolerability.3-7
Highly potent, 8* Actair®
demonstrated results as early
as 8 weeks, and meaningful
improvements over time for
patients.5,6**
Actair®, a House Dust
Mite tablet, showed carry-over
effects on patient health
following treatment cessation.7*
Let's get personal
*Stallergenes Greer in vitro study. Highly potent based on allergen potency evaluated quantitatively without any validated clinical consequences.
**Efficacy data over only 12 months of treatment with Actair® are available for adolescents (12–17 years) and adults.
*Demonstrated efficacy compared with placebo in adults maintained 1 year after 1 year of treatment (exploratory endpoint).
“I'm Tomasz. At age 32,
I've taken antihistamine
tablets and nasal steroids
most of my life, just to
cope with the symptoms I
live with day and night, at
home and in my studio."
Treat him
The following medical history is fictional. The presentation is based on typically occurring
circumstances. The treatment and the success of the therapy depicted represent an idealized
course. This possible course of therapy has been confirmed by clinical studies. Nevertheless, each
patient and each course of disease is highly individual and a corresponding effect cannot be
expected and guaranteed for all patients.

32 year old male

UK Painter & Decorator

Married, 2 kids

Passion for Italian art and cuisine

Before
“I'm Tomasz. At age 32, I am
starting AIT today. I've taken
antihistamine tablets and nasal
steroids most of my life, just
to cope with the symptoms I
live with day and night, at
home and in my studio. For
years I've had no escape
from horrible, disruptive
symptoms triggered by
house dust mites. Can things
finally be different?”​
Help him to live a life beyond allergy
Clinical History

Symptoms of allergic rhinitis: itchy eyes
and nose, runny nose, cough, occasional
wheezing with peak towards the Fall

Treated for 4 months with cetirizine once
daily with good relief of symptoms, but
complains of insufficient lasting relief and
sleepiness with impact on work
performance.

Fear of injections

​No other past medical history including
food allergy or eczema.​

Clinical Exam

Itchy eyes, runny nose, itchy
nose, nasal blockage , cough
and mucosal inflammation

Diagnosis
Diagnosis:
HDM-induced
moderate to
severe persistent
allergic rhinitis
Treat him for allergic rhinitis
Physician
Recommendation
Allergen Avoidance
Symptomatic Treatment
Subcutaneous immunotherapy
Sublingual immunotherapy liquid formulation
Sublingual immunotherapy tablet formulation
Patient's Choice

Symptomatic Treatment

Sublingual immunotherapy
liquid formulation

Initiate Treatment
Early results
“My symptoms have gone, like dust.
I haven't reached for an antihistamine
in weeks.
I can breathe deeply, think clearly.
My kids get proper playtime with
me now without allergy symptoms
striking and stopping their fun.
Oh, and I started a new
painting; I have a good feeling
about this new direction.”
Maintenance
Maintained
Results
“I finished my AIT course 6
months ago and I’ve been busy
painting, with less congestion
and itchy eyes clouding
my inspiration. Tonight, I’m
celebrating my first gallery
opening with the whole family.
Two years ago I couldn't
imagine this achievement was
possible, but here I am.”
Life beyond allergy
Every patient
deserves to live a life
beyond allergy
Potential AIT benefits over time
Theoretical concept adapted with permission from Spriggs K. et al.9
Actair® is a sublingual
immunotherapy tablet with
a flexible initiation protocol to
improve tolerability.3-7
Highly potent8* , Actair®
demonstrated results as early
as 8 weeks, and meaningful
improvements over time for
patients.5,6**
Actair®, a House Dust
Mite tablet, showed
carry-over effects on
patient health
following treatment
cessation.7**
Learn more about safety
*Stallergenes Greer in vitro study. Highly potent based on allergen potency evaluated quantitatively without any validated clinical consequences.
**Efficacy data over only 12 months of treatment with Actair® are available for adolescents (12–17 years) and adults.
***Demonstrated efficacy compared with placebo in adults maintained 1 year after 1 year of treatment (exploratory endpoint).
Every patient
deserves to live a life
beyond allergy
Summary of the safety profile5
Assessment of adverse reactions from clinical study data is based
on trials in which 3007 patients received at least one dose of
house dust mite sublingual tablet. The most frequent adverse
reactions were application site reactions: oral pruritus, mouth
oedema, throat irritation and ear pruritus.

Adverse reactions were generally mild or moderate.
They mostly occurred within the first days of treatment
and decreased over the next 3 months.

Please consult section 4.8 of the SmPC for full safety details.
Let us tell you all about it
ACTAIR 100 IR, sublingual tablets or ACTAIR 100 IR & 300 IR, sublingual tablets or ACTAIR 300 IR, sublingual tablets is :
• indicated in adolescents (12-17 years) and adults for treatment of moderate to severe house dust mite-induced allergic rhinitis or rhinoconjunctivitis, diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE). ACTAIR 100 IR is intended only for the dose escalation period (see also section 4.2). … Read more Read less